299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03925194
(ClinicalTrials.gov)
October 1, 202119/4/2019A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CFA Phase IIa, Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With Cystic FibrosisCystic Fibrosis, 10011762Drug: AnakinraHeidelberg UniversityNULLNot yet recruiting12 YearsN/AAll52Phase 2Germany
2EUCTR2016-004786-80-DE
(EUCTR)
30/06/2017Tolerability and Efficacy of Anakinra in patients with cystic fibrosis.A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. - ANAKIN Cystic fibrosis
MedDRA version: 20.0;Level: LLT;Classification code 10028141;Term: Mucoviscidosis;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Kineret
INN or Proposed INN: ANAKINRA
Ruprecht-Karls-University Heidelberg, Medical FacultyNULLNA Female: yes
Male: yes
52 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noGermany